Ben Lamm, CEO of the Dallas-based company with an estimated value over $10 billion, said the successful gene-editing of lab ...
Scientists working to bring back the woolly mammoth have successfully created genetically modified mice with thick, woolly ...
Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of ...
Using CRISPR, a powerful gene-editing tool, they targeted ten genes in mice associated with traits like hair length, texture, ...
Leerink Partners Global Healthcare Conference, Miami Wednesday, March 12, 2025 (1x1 meetings) The live and archived webcasts will be accessible from the Company’s website at https://brightmindsbio.com ...
The replay of the webcast will be accessible for 90 days. Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders.
GlobalData on MSN14h
Biohaven’s pivotal bipolar drug trial fails, stock takes hitBiohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking ...
Faster Clinical Translation and Commercialization of Therapies Derived From iPSC Technology GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and ...
SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. (PRNewsfoto ...
The replay of the webcast will be accessible for 90 days. Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders.
Presentation webcasts can be accessed on the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback